Chugai Pharmaceutical Co., Ltd. Share Price
Stocks
4519
JP3519400000
Pharmaceuticals
OTC Markets Traded|
Delayed
Japan Exchange
07:12:44 16/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 6,425.00 JPY | -1.15% |
|
-0.82% | -22.08% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-18 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 10,694B 68.94B 59.72B 56.47B 51.12B 95.95B 6,613B 96.67B 674B 259B 3,353B 259B 253B | P/E 2026 * |
21.1x | P/E 2027 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 9,784B 63.08B 54.64B 51.66B 46.77B 87.79B 6,051B 88.45B 617B 237B 3,068B 237B 232B | EV / Sales 2026 * |
7.05x | EV / Sales 2027 * | 6.24x |
| Free-Float |
38.12% | Yield 2026 * |
2.09% | Yield 2027 * | 2.39% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4519 | Delayed | |
OTC Markets
| CHGCF | Delayed | |
|
Mexican S.E.
| 4519 N | End-of-day quote | |
|
Tradegate
| CUP | Real-time | |
|
Deutsche Boerse AG
| CUP | Delayed | |
|
Börse Stuttgart
| CUP | Delayed | |
|
Boerse Muenchen
| CUP | Real-time |
Last Transcript: Chugai Pharmaceutical Co., Ltd.
| 1 day | -1.18% | ||
| 1 week | -0.82% | ||
| Current month | -7.09% | ||
| 1 month | -6.42% | ||
| 3 months | -14.62% | ||
| 6 months | -29.55% | ||
| Current year | -22.08% |
| 1 week | 6,293 |  | 6,533 |
| 1 month | 6,293 | | 7,141 |
| Current year | 6,293 | | 10,700 |
| 1 year | 6,250 | | 10,700 |
| 3 years | 4,197 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 28/02/2021 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 27/03/2024 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 29/02/2020 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 27/03/2024 |
| Director/Board Member | 51 | 28/02/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.15% | -0.82% | -4.70% | +44.08% | 68.94B | |
| -0.19% | +1.09% | +51.85% | +97.36% | 1,013B | |
| +0.33% | -0.71% | +50.62% | +65.50% | 644B | |
| +0.49% | +5.73% | +20.88% | +72.92% | 465B | |
| -0.22% | +2.88% | +38.48% | +37.98% | 352B | |
| -0.07% | +1.82% | +16.57% | +23.39% | 264B | |
| -0.31% | +2.02% | +6.15% | +10.75% | 253B | |
| -1.53% | -4.46% | +36.90% | +44.08% | 203B | |
| -1.60% | -5.51% | -22.30% | -58.60% | 188B | |
| +0.49% | -0.23% | +30.00% | +93.34% | 181B | |
| Average | -0.19% | -1.20% | +22.44% | +43.08% | 363.26B | |
| Weighted average by Cap. | +0.38% | -0.03% | +33.77% | +59.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 8.95B 7.75B 7.33B 6.64B 12.46B 858B 12.55B 87.48B 33.66B 435B 33.62B 32.87B | 1,529B 9.86B 8.54B 8.07B 7.31B 13.72B 945B 13.82B 96.34B 37.06B 479B 37.02B 36.2B |
| Net income | 506B 3.26B 2.83B 2.67B 2.42B 4.54B 313B 4.58B 31.9B 12.27B 159B 12.26B 11.99B | 583B 3.76B 3.26B 3.08B 2.79B 5.23B 361B 5.27B 36.76B 14.14B 183B 14.13B 13.81B |
| Net Debt | -910B -5.87B -5.08B -4.81B -4.35B -8.17B -563B -8.23B -57.35B -22.06B -285B -22.04B -21.55B | -1,151B -7.42B -6.43B -6.08B -5.5B -10.32B -712B -10.4B -72.51B -27.9B -361B -27.87B -27.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/09/26 | JP¥6,425.00 | -1.15% | 1,570,800 |
| 15/09/26 | JP¥6,500.00 | +1.34% | 1,907,400 |
| 14/09/26 | JP¥6,414.00 | -0.12% | 1,755,500 |
| 11/09/26 | JP¥6,422.00 | +0.06% | 3,008,400 |
| 10/09/26 | JP¥6,418.00 | -0.90% | 3,141,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
